Lisa Leypoldt

15PUBLICATIONS
79CO-AUTHORS
Medical mycologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)Te ariā o ngā tauira panoni hauora o te Māori (Māori theory of change models for health)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

|Feb 17, 2026
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

C Riedhammer, M Truger, H Lee

|Feb 13, 2026
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Jan H Frenking, Christine Riedhammer, Thomas Hielscher

|Nov 01, 2025
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt

|Oct 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

Niccolò Bolli, Mattia D'Agostino, Tina Bagratuni

|Aug 26, 2025
Understanding quality of life under talquetamab: Learning to measure what matters.

Lisa Leypoldt, Meral Beksac, Aurore Perrot

Pageof 3

Frequent Collaborators

7 joint publications

Katja Weisel

5 joint publications

Hartmut Goldschmidt

5 joint publications

Hans Salwender

5 joint publications

K Martin Kortüm